A Phase 2 interventional study of Asciminib add-on and Imatinib in CML, Chronic Myelogenous Leukemia and Leukemia, Myeloid Chronic, sponsored by Novartis Pharmaceuticals. Completed at 30 sites in 15 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 1 open to participants now, 5 under way, none of them phase 3. imatinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Among the 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 26th largest by enrollment of the 83 interventional ones that give a count, is the only one that started in 2018, is one of 48 in phase 2, and was the 89th registered.
894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →1 of the 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive is open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Austria and 26 more countries
Ages 7–100
By country, each count listing its studies:
imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
93 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 56 · Phase 3 15 · Phase 4 8
First in 1999; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 104 is above the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 60 across the 83 interventional studies. Of the 72 that completed or were terminated, 20 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 93 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis: 9 open now, 13 under way, 2 of them phase 3. Of 73 finished, 35 (48%) have results posted.
Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, this one is the 28th largest by enrollment of the 63 interventional ones that give a count, is the only one that started in 2018, is one of 19 in phase 2, and was the 61st registered.
Novartis’s Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, from their registry updates:
Among Novartis’s 92 in Leukemia, Myelogenous, Chronic, BCR-ABL Positive:
This tab as a report to print or save as PDF → With an account.
To evaluate efficacy, safety and pharmacokinetic profile of asciminib 40mg+imatinib or asciminib 60mg+imatinib versus continued imatinib and versus nilotinib in pre-treated patients with Chronic Myeloid Leukemia in chronic phase (CML-CP). An asciminib single agent arm (80 mg daily) was added after the primary analysis to evaluate if asciminib alone could lead to MR4.5 patients in Imatinib for at least one year who have never achieved deep molecular response (DMR).
The study was a Phase 2, multi-center, open-label, randomized study of asciminib in two different doses (40 mg or 60 mg) in combination with imatinib 400 mg versus continued imatinib versus switch to nilotinib in participants with chronic myeloid leukemia in chronic phase (CML-CP) who had been previously treated with imatinib first line therapy for at least one year and had not achieved deep molecular response (DMR). Eligible participants were randomized 1:1:1:1 to receive asciminib 60 mg once daily (QD) as add-on therapy to imatinib 400 mg QD, or 40 mg QD as add-on therapy to imatinib 400 mg QD, or to continue imatinib 400 mg QD, or to switch to nilotinib 300 mg twice a day (BID). During the trial, there was no switch allowed. It was just at the moment of the randomization that the participants were selected to asciminib add-on arms or nilotinib.
Participants on the imatinib continuation arm who had not achieved MR4.5 at 48 weeks were allowed to cross-over ((CO) to receive the add-on treatment within 4 weeks after week 48 visit to receive the asciminib 60 mg combination add-on treatment, as this dose provided higher exposure. The cross-over was at the discretion of the investigator and the participant. Apart from a polymerase chain reaction (PCR) result of below MR4.5 at Week 48 visit, there were no other entry criteria for the cross-over part. Participants on nilotinib were not allowed to cross-over to receive the add-on treatment.
Participants on the study continued on the allocated treatment until treatment failure, intolerability, or for up to 96 weeks (in arms 1 to 4) after the last participant had received the first dose of treatment. After the last dose was received, every participant was followed up for safety for 30 days.
Inclusion Criteria:
For Korea only:
(i) a minimum of one year (12 calendar months) of prior treatment with imatinib for patients with BCR::ABL1 levels > 0.1%, ≤ 1% IS at the time of randomization.
(ii) a minimum of two years (24 calendar months) of prior treatment with imatinib for patients with BCR::ABL 1 levels > 0.01%, ≤ 0.1% IS at the time of randomization.
Key Exclusion Criteria:
Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Asciminib 60 mg taken once daily in combination with Imatinib 400 mg taken once daily
Drug: Asciminib add-on · Drug: Imatinib
Asciminib 40 mg taken once daily in combination with Imatinib 400 mg taken once daily
Drug: Asciminib add-on · Drug: Imatinib
Imatinib 400 mg taken once daily
Drug: Imatinib
Nilotinib 300 mg taken twice daily
Drug: Nilotinib
Asciminib 80 mg taken once daily
Drug: Asciminib 80mg QD (asciminib single agent (ASAC))
Asciminib was supplied as 40 mg and 20 mg tablets and taken orally once daily.
Also known as: ABL001 (asciminib)
Imatinib was supplied as 400 mg and 100 mg tablets and taken orally once daily.
Also known as: STI571
Nilotinib was supplied as 150 mg and 200 mg hard gelatin capsules and taken orally twice daily.
Also known as: AMN107
Asciminib was supplied as 40 mg and 20 mg tablets and taken orally once daily (in the fasted state) on a continuous schedule (QD).
Also known as: ABL001
Molecular Response (MR)^4.5 Rate at 48 Weeks and Difference in Rate Between Asciminib + Imatinib and Imatinib Alone
Percentage of participants still treated with the randomized treatment at 48 weeks and are in MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) at 48 weeks (± assessment window), among all participants in the asciminib add-on arms vs imatinib arm.
Time frame: at Week 48
Rate of MR^4.5 at 48 Weeks (Asciminib add-on Arms vs Nilotinib)
Percentage of participants in MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) at 48 weeks in asciminib add-on arms vs nilotinib arm.
Time frame: at Week 48
Rate of MR^4.5 by 48 Weeks (Randomized Arms)
Best observed MR\^4.5 rate (BCR::ABL1 ratio of ≤ 0.0032%) up to 48 weeks, i.e. the percentage of participants who achieved MR 4.5 anytime up to 48 weeks.
Time frame: by 48 weeks
Rate of MR^4.5 at 96 Weeks (Randomized Arms) and Difference in Rate Between Asciminib + Imatinib and Nilotinib Alone
Percentage of participants in MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) at 96 weeks in asciminib add-on arms vs nilotinib arm.
Time frame: at Week 96
Rate of MR^4.5 by 96 Weeks (Randomized Arms)
Best observed MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) rate up to 96 weeks, i.e. the percentage of participants who achieved MR\^4.5 anytime up to 96 weeks.
Time frame: by 96 weeks
Sustained MR^4.5 From at 96 Weeks (Randomized Arms)
Sustained MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) rate was defined as the percentage of participants who were in MR4.5 at 48 weeks and 96 weeks and who had no loss of MR4.5 in between those 2 time points.
Time frame: at 96 weeks
Time to MR^4.5 (Randomized Arms)
Time to MR\^4.5 is the time from first dose to first MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) computed only for participants who achieved MR\^4.5 at least once before the cut-off date.
Time frame: 96 weeks after the last participant received the first study dose
Duration of MR^4.5 (Randomized Arms)
Duration of MR\^4.5 was defined as the time from the first documented MR\^4.5 and the end date of MR\^4.5, i.e., the earliest date of loss of MR\^4.5 or CML-related death. Confirmed loss of MR\^4.5 is defined as an increase of the BCR::ABL1 ratio to \>0.0032% in two consecutive blood samples, by International Scale.
Time frame: 96 weeks after the last participant received the first study dose
Pharmacokinetic Profile of Asciminib 40/60 mg and Imatinib When Administered in Combination - Cmax (Randomized Arms)
The maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass x volume-1).
Time frame: Week 2 Day 14: pre-dose (0h), 1h, 2h, 3hr 4h and 8h post-dose; Week 4 Day 28: pre-dose (0h) 2h, 3h, 4h post-dose
Pharmacokinetic Profile of Asciminib 40/60 mg and Imatinib When Administered in Combination - Tmax (Randomized Arms)
The time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration (time).
Time frame: Week 2 Day 14: pre-dose (0h), 1h, 2h, 3hr 4h and 8h post-dose; Week 4 Day 28: pre-dose (0h) 2h, 3h, 4h post-dose
Pharmacokinetic Profile of Asciminib 40/60 mg and Imatinib When Administered in Combination - Cmin (Randomized Arms)
Minimum drug plasma(serum/blood) concentration
Time frame: Week 2 Day 14: pre-dose (0h), Week 4 Day 28: pre-dose (0h)
Pharmacokinetic Profile of Asciminib 40/60 mg and Imatinib When Administered in Combination - AUClast (Randomized Arms)
The AUC from time zero to the last measurable concentration sampling time (Tlast) (mass x time x volume-1).
Time frame: Week 2 Day 14: pre-dose (0h), 1h, 2h, 3hr 4h and 8h post-dose
Pharmacokinetic Profile of Asciminib 40/60 mg and Imatinib When Administered in Combination - AUCtau (Randomized Arms)
The AUC calculated to the end of a dosing interval (tau) at steady-state
Time frame: Week 2 Day 14: pre-dose (0h), 1h, 2h, 3hr 4h and 8h post-dose
Molecular Response (MR) 4.5 Rate at 48 Weeks (Asciminib Single Agent Cohort (ASAC))
Percentage of participants on asciminib 80 mg QD with MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) at 48 weeks.
Time frame: at Week 48
Time to MR^4.5 (ASAC)
Time from first dose of asciminib 80 mg QD to first MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) computed only for participants who achieved MR\^4.5.
Time frame: 48 weeks after the last enrolled participant (asciminib 80 mg cohort) received the first study dose
Duration of MR^4.5 (ASAC)
Time from first MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) until confirmed loss of MR\^4.5 or CML-related death.
Time frame: 48 weeks after the last enrolled participant (asciminib 80 mg cohort) received the first study dose
Pharmacokinetic Profile of Asciminib 80mg QD - Cmax (ASAC)
The maximum (peak) observed plasma drug concentration after oral dose administration (mass x volume-1).
Time frame: Week 2 Day 14: 0h (pre-dose), 1h, 2h, 3h, 4h, 8h post-dose; Week 4 Day 28: 0h (pre-dose), 2h, 3h, 4h post-dose
Pharmacokinetic Profile of Asciminib 80mg QD - Tmax (ASAC)
The time to reach maximum (Cmax) plasma drug concentration after oral dose administration (time).
Time frame: Week 2 Day 14: 0h (pre-dose), 1h, 2h, 3h, 4h, 8h post-dose; Week 4 Day 28: 0h (pre-dose), 2h, 3h, 4h post-dose
Pharmacokinetic Profile of Asciminib 80mg QD - Cmin (ASAC)
Minimum drug plasma (serum/blood) concentration
Time frame: Week 2 Day 14: 0h (pre-dose), Week 4 Day 28: 0h (pre-dose)
Pharmacokinetic Profile of Asciminib 80mg QD - AUClast (ASAC)
The AUC from time zero to the last measurable concentration sampling time (Tlast) (mass x time x volume-1).
Time frame: Week 2 Day 14: 0h (pre-dose), 1h, 2h, 3h, 4h, 8h post-dose
Pharmacokinetic Profile of Asciminib 80mg QD - AUCtau (ASAC)
The AUC calculated to the end of a dosing interval (tau) at steady-state (amount x time x volume-1)
Time frame: Week 2 Day 14: 0h (pre-dose), 1h, 2h, 3h, 4h, 8h post-dose
All the participants were enrolled at 30 sites.
| Milestone | Asciminib 40mg QD + Imatinib 400mg QD | Asciminib 60mg QD + Imatinib 400mg QD | Imatinib 400mg QD | Nilotinib 300mg BID | Asciminib 80mg QD |
|---|---|---|---|---|---|
| Started | 21 | 21 | 21 | 21 | 20 |
| Treated | 21 | 21 | 20 | 21 | 20 |
| Discontinued from treatment | 3 | 5 | 16 | 10 | 1 |
| Switched from imatinib to asciminib 60 mg combo | 0 | 14 | 0 | 0 | 0 |
| Completed | 18 | 16 | 4 | 11 | 19 |
| Not completed | 3 | 5 | 17 | 10 | 1 |
| Withdrew: Adverse event | 0 | 3 | 0 | 7 | 1 |
| Withdrew: Withdrawal by subject | 2 | 2 | 1 | 3 | 0 |
| Withdrew: Physician decision | 0 | 0 | 14 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Not treated | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 1 | 0 | 0 |
Percentage of participants still treated with the randomized treatment at 48 weeks and are in MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) at 48 weeks (± assessment window), among all participants in the asciminib add-on arms vs imatinib arm.
| Percentage of participants | Asciminib 40mg QD + Imatinib 400mg QD | Asciminib 60mg QD + Imatinib 400mg QD | Imatinib 400mg QD |
|---|---|---|---|
| Molecular Response (MR)^4.5 Rate at 48 Weeks and Difference in Rate Between Asciminib + Imatinib and Imatinib Alone | 19.0 (6.8 to 38.4) | 28.6 (13.2 to 48.7) | 0.0 (0.0 to 13.3) |
Percentage of participants in MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) at 48 weeks in asciminib add-on arms vs nilotinib arm.
| Percentage of participants | Asciminib 40mg QD + Imatinib 400mg QD | Asciminib 60mg QD + Imatinib 400mg QD | Nilotinib 300mg BID |
|---|---|---|---|
| Rate of MR^4.5 at 48 Weeks (Asciminib add-on Arms vs Nilotinib) | 19.0 (6.8 to 38.4) | 28.6 (13.2 to 48.7) | 4.8 (0.2 to 20.7) |
Best observed MR\^4.5 rate (BCR::ABL1 ratio of ≤ 0.0032%) up to 48 weeks, i.e. the percentage of participants who achieved MR 4.5 anytime up to 48 weeks.
| Percentage of participants | Asciminib 60mg QD + Imatinib 400mg QD | Asciminib 40mg QD + Imatinib 400mg QD | Imatinib 400mg QD | Nilotinib 300mg BID |
|---|---|---|---|---|
| Rate of MR^4.5 by 48 Weeks (Randomized Arms) | 19.0 (6.8 to 38.4) | 28.6 (13.2 to 48.7) | 0 (0.0 to 13.3) | 14.3 (4.0 to 32.9) |
Percentage of participants in MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) at 96 weeks in asciminib add-on arms vs nilotinib arm.
| Percentage of participants | Asciminib 40mg QD + Imatinib 400mg QD | Asciminib 60mg QD + Imatinib 400mg QD | Nilotinib 300mg BID |
|---|---|---|---|
| Rate of MR^4.5 at 96 Weeks (Randomized Arms) and Difference in Rate Between Asciminib + Imatinib and Nilotinib Alone | 19.0 (6.8 to 38.4) | 19.0 (6.8 to 38.4) | 9.5 (1.7 to 27.1) |
Best observed MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) rate up to 96 weeks, i.e. the percentage of participants who achieved MR\^4.5 anytime up to 96 weeks.
| Percentage of participants | Asciminib 60mg QD + Imatinib 400mg QD | Asciminib 40mg QD + Imatinib 400mg QD | Imatinib 400mg QD | Nilotinib 300mg BID |
|---|---|---|---|---|
| Rate of MR^4.5 by 96 Weeks (Randomized Arms) | 28.6 (13.2 to 48.7) | 28.6 (13.2 to 48.7) | 9.5 (1.7 to 27.1) | 19.0 (6.8 to 38.4) |
Sustained MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) rate was defined as the percentage of participants who were in MR4.5 at 48 weeks and 96 weeks and who had no loss of MR4.5 in between those 2 time points.
| Percentage of participants | Asciminib 60mg QD + Imatinib 400mg QD | Asciminib 40mg QD + Imatinib 400mg QD | Imatinib 400mg QD | Nilotinib 300mg BID |
|---|---|---|---|---|
| Sustained MR^4.5 From at 96 Weeks (Randomized Arms) | 14.3 (4.0 to 32.9) | 9.5 (1.7 to 27.1) | 0 (0.0 to 13.3) | 4.8 (0.2 to 20.7) |
Time to MR\^4.5 is the time from first dose to first MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) computed only for participants who achieved MR\^4.5 at least once before the cut-off date.
| Weeks | Asciminib 60mg QD + Imatinib 400mg QD | Asciminib 40mg QD + Imatinib 400mg QD | Imatinib 400mg QD | Nilotinib 300mg BID |
|---|---|---|---|---|
| Time to MR^4.5 (Randomized Arms) | 24.6 (8 to 120) | 12.4 (12 to 36) | 66.4 (61 to 72) | 36.3 (24 to 108) |
Duration of MR\^4.5 was defined as the time from the first documented MR\^4.5 and the end date of MR\^4.5, i.e., the earliest date of loss of MR\^4.5 or CML-related death. Confirmed loss of MR\^4.5 is defined as an increase of the BCR::ABL1 ratio to \>0.0032% in two consecutive blood samples, by International Scale.
| Weeks | Asciminib 60mg QD + Imatinib 400mg QD | Asciminib 40mg QD + Imatinib 400mg QD | Imatinib 400mg QD | Nilotinib 300mg BID |
|---|---|---|---|---|
| Duration of MR^4.5 (Randomized Arms) | 24.1 (11.9 to NA) | NA (47.9 to NA) | 24.4 (23.6 to NA) | NA (11.7 to NA) |
The maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass x volume-1).
| ng/mL | Asciminib 40mg QD + Imatinib 400mg QD (Asciminib) | Asciminib 40mg QD + Imatinib 400mg QD (Imatinib) | Asciminib 60mg QD + Imatinib 400mg QD (Asciminib) | Asciminib 60mg QD + Imatinib 400mg QD (Imatinib) |
|---|---|---|---|---|
| Week 2 Day 14 | 701.75 ± 32.16 | 2562.96 ± 29.49 | 1078.92 ± 34.48 | 2237.83 ± 30.42 |
| Week 4 Day 28 | 720.21 ± 25.53 | 2285.89 ± 29.28 | 1000.70 ± 33.50 | 2165.80 ± 41.41 |
The time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration (time).
| hour (hr) | Asciminib 40mg QD + Imatinib 400mg QD (Asciminib) | Asciminib 40mg QD + Imatinib 400mg QD (Imatinib) | Asciminib 60mg QD + Imatinib 400mg QD (Asciminib) | Asciminib 60mg QD + Imatinib 400mg QD (Imatinib) |
|---|---|---|---|---|
| Week 2 Day 14 | 2.76 ± 57.38 | 3.05 ± 36.31 | 2.30 ± 44.15 | 2.40 ± 59.04 |
| Week 4 Day 28 | 2.67 ± 29.62 | 2.61 ± 29.97 | 2.61 ± 28.33 | 2.80 ± 25.99 |
Minimum drug plasma(serum/blood) concentration
| ng/mL | Asciminib 40mg QD + Imatinib 400mg QD (Asciminib) | Asciminib 40mg QD + Imatinib 400mg QD (Imatinib) | Asciminib 60mg QD + Imatinib 400mg QD (Asciminib) | Asciminib 60mg QD + Imatinib 400mg QD (Imatinib) |
|---|---|---|---|---|
| Week 2 Day 14 | 175 ± 41.2 | 1050 ± 39.1 | 221 ± 62.7 | 904 ± 62.4 |
| Week 4 Day 28 (n = 20, 20, 18, 18) | 152 ± 58.5 | 962 ± 39.3 | 249 ± 52.6 | 894 ± 39.8 |
The AUC from time zero to the last measurable concentration sampling time (Tlast) (mass x time x volume-1).
| hr*ng/mL | Asciminib 40mg QD + Imatinib 400mg QD (Asciminib) | Asciminib 40mg QD + Imatinib 400mg QD (Imatinib) | Asciminib 60mg QD + Imatinib 400mg QD (Asciminib) | Asciminib 60mg QD + Imatinib 400mg QD (Imatinib) |
|---|---|---|---|---|
| Pharmacokinetic Profile of Asciminib 40/60 mg and Imatinib When Administered in Combination - AUClast (Randomized Arms) | 8683.46 ± 47.19 | 37900.51 ± 47.43 | 11889.74 ± 38.07 | 34090.56 ± 44.54 |
The AUC calculated to the end of a dosing interval (tau) at steady-state
| hr*ng/mL | Asciminib 40mg QD + Imatinib 400mg QD (Asciminib) | Asciminib 40mg QD + Imatinib 400mg QD (Imatinib) | Asciminib 60mg QD + Imatinib 400mg QD (Asciminib) | Asciminib 60mg QD + Imatinib 400mg QD (Imatinib) |
|---|---|---|---|---|
| Pharmacokinetic Profile of Asciminib 40/60 mg and Imatinib When Administered in Combination - AUCtau (Randomized Arms) | 9137.59 ± 37.90 | 43794.83 ± 23.93 | 12315.06 ± 39.45 | 37440.73 ± 11.13 |
Percentage of participants on asciminib 80 mg QD with MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) at 48 weeks.
| Percentage of participants | Asciminib 80mg QD |
|---|---|
| Molecular Response (MR) 4.5 Rate at 48 Weeks (Asciminib Single Agent Cohort (ASAC)) | 35.0 (17.7 to 55.8) |
Time from first dose of asciminib 80 mg QD to first MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) computed only for participants who achieved MR\^4.5.
| Weeks | Asciminib 80mg QD |
|---|---|
| Time to MR^4.5 (ASAC) | 24.3 (8 to 61) |
Time from first MR\^4.5 (BCR::ABL1 ratio of ≤ 0.0032%) until confirmed loss of MR\^4.5 or CML-related death.
| Weeks | Asciminib 80mg QD |
|---|---|
| Duration of MR^4.5 (ASAC) | 24.1 (0 to 76) |
The maximum (peak) observed plasma drug concentration after oral dose administration (mass x volume-1).
| ng/mL | Asciminib 80mg QD |
|---|---|
| Week 2 Day 14 | 1319.32 ± 39.70 |
| Week 4 Day 28 | 1250.01 ± 47.95 |
The time to reach maximum (Cmax) plasma drug concentration after oral dose administration (time).
| hour (hr) | Asciminib 80mg QD |
|---|---|
| Week 2 Day 14 | 1.93 ± 89.09 |
| Week 4 Day 28 | 2.22 ± 24.38 |
Minimum drug plasma (serum/blood) concentration
| ng/mL | Asciminib 80mg QD |
|---|---|
| Week 2 Day 14 | 169 ± 53.1 |
| Week 4 Day 28 (n = 18) | 171 ± 52.1 |
The AUC from time zero to the last measurable concentration sampling time (Tlast) (mass x time x volume-1).
| hr*ng/mL | Asciminib 80mg QD |
|---|---|
| Pharmacokinetic Profile of Asciminib 80mg QD - AUClast (ASAC) | 13363.35 ± 48.33 |
The AUC calculated to the end of a dosing interval (tau) at steady-state (amount x time x volume-1)
| hr*ng/mL | Asciminib 80mg QD |
|---|---|
| Pharmacokinetic Profile of Asciminib 80mg QD - AUCtau (ASAC) | 13725.57 ± 47.31 |
Collected over From first dose of study treatment to 30 days after last dose of study treatment for a minimum of 48 weeks and a maximum of 196 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| On-treatment Period Asciminib 40 mg + Imatinib | 1/21 (4.8%) | 3/21 (14.3%) | 20/21 (95.2%) |
| On-treatment Period Asciminib 60 mg + Imatinib | 0/21 (0%) | 4/21 (19%) | 18/21 (85.7%) |
| On-treatment Period Imatinib | 0/20 (0%) | 1/20 (5%) | 13/20 (65%) |
| On-treatment Period Nilotinib | 0/21 (0%) | 5/21 (23.8%) | 21/21 (100%) |
| On-treatment Period Asciminib 80 mg | 0/20 (0%) | 2/20 (10%) | 18/20 (90%) |
| On-treatment Period Switched From Imatinib to Asciminib 60 mg Combo | 0/14 (0%) | 1/14 (7.1%) | 10/14 (71.4%) |
| Post-treatment Period Asciminib 40 mg + Imatinib | 0/18 (0%) | 0/18 (0%) | 0/18 (0%) |
| Post-treatment Period Asciminib 60 mg + Imatinib | 0/18 (0%) | 0/18 (0%) | 0/18 (0%) |
| Post-treatment Period Imatinib | 0/19 (0%) | 0/19 (0%) | 0/19 (0%) |
| Post-treatment Period Nilotinib | 0/19 (0%) | 0/19 (0%) | 0/19 (0%) |
| Post-treatment Period Asciminib 80 mg | 0/20 (0%) | 0/20 (0%) | 0/20 (0%) |
| Post-treatment Period Switched From Imatinib to Asciminib 60 mg Combo | 0/14 (0%) | 0/14 (0%) | 0/14 (0%) |
| Event | On-treatment Period Asciminib 40 mg + Imatinib | On-treatment Period Asciminib 60 mg + Imatinib | On-treatment Period Imatinib | On-treatment Period Nilotinib | On-treatment Period Asciminib 80 mg | On-treatment Period Switched From Imatinib to Asciminib 60 mg Combo | Post-treatment Period Asciminib 40 mg + Imatinib | Post-treatment Period Asciminib 60 mg + Imatinib | Post-treatment Period Imatinib | Post-treatment Period Nilotinib | Post-treatment Period Asciminib 80 mg | Post-treatment Period Switched From Imatinib to Asciminib 60 mg Combo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prostatic adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/21 | 0/21 | 0/20 | 0/21 | 0/20 | 1/14 | — | — | — | — | — | — |
| Oedematous pancreatitisGastrointestinal disorders | 0/21 | 0/21 | 0/20 | 0/21 | 1/20 | 0/14 | — | — | — | — | — | — |
| Abscess intestinalInfections and infestations | 0/21 | 0/21 | 1/20 | 0/21 | 0/20 | 0/14 | — | — | — | — | — | — |
| Diverticulitis intestinal perforatedInfections and infestations | 0/21 | 0/21 | 1/20 | 0/21 | 0/20 | 0/14 | — | — | — | — | — | — |
| Urinary tract infectionInfections and infestations | 1/21 | 0/21 | 0/20 | 0/21 | 1/20 | 0/14 | — | — | — | — | — | — |
| Cardiac arrestCardiac disorders | 1/21 | 0/21 | 0/20 | 0/21 | 0/20 | 0/14 | — | — | — | — | — | — |
| Appendiceal mucocoeleGastrointestinal disorders | 0/21 | 1/21 | 0/20 | 0/21 | 0/20 | 0/14 | — | — | — | — | — | — |
| IleusGastrointestinal disorders | 0/21 | 0/21 | 0/20 | 1/21 | 0/20 | 0/14 | — | — | — | — | — | — |
| PancreatitisGastrointestinal disorders | 0/21 | 1/21 | 0/20 | 0/21 | 0/20 | 0/14 | — | — | — | — | — | — |
| Pancreatitis acuteGastrointestinal disorders | 0/21 | 0/21 | 0/20 | 1/21 | 0/20 | 0/14 | — | — | — | — | — | — |
| Event | On-treatment Period Asciminib 40 mg + Imatinib | On-treatment Period Asciminib 60 mg + Imatinib | On-treatment Period Imatinib | On-treatment Period Nilotinib | On-treatment Period Asciminib 80 mg | On-treatment Period Switched From Imatinib to Asciminib 60 mg Combo | Post-treatment Period Asciminib 40 mg + Imatinib | Post-treatment Period Asciminib 60 mg + Imatinib | Post-treatment Period Imatinib | Post-treatment Period Nilotinib | Post-treatment Period Asciminib 80 mg | Post-treatment Period Switched From Imatinib to Asciminib 60 mg Combo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 4/21 | 9/21 | 2/20 | 5/21 | 2/20 | 2/14 | — | — | — | — | — | — |
| RashSkin and subcutaneous tissue disorders | 4/21 | 1/21 | 1/20 | 8/21 | 4/20 | 0/14 | — | — | — | — | — | — |
| NauseaGastrointestinal disorders | 7/21 | 3/21 | 2/20 | 3/21 | 2/20 | 2/14 | — | — | — | — | — | — |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/21 | 0/21 | 1/20 | 1/21 | 6/20 | 2/14 | — | — | — | — | — | — |
| Abdominal pain upperGastrointestinal disorders | 2/21 | 1/21 | 0/20 | 2/21 | 5/20 | 0/14 | — | — | — | — | — | — |
| Lipase increasedInvestigations | 4/21 | 4/21 | 3/20 | 2/21 | 5/20 | 2/14 | — | — | — | — | — | — |
| DiarrhoeaGastrointestinal disorders | 5/21 | 3/21 | 3/20 | 1/21 | 0/20 | 2/14 | — | — | — | — | — | — |
| Alanine aminotransferase increasedInvestigations | 2/21 | 1/21 | 0/20 | 5/21 | 2/20 | 0/14 | — | — | — | — | — | — |
| MyalgiaMusculoskeletal and connective tissue disorders | 5/21 | 1/21 | 1/20 | 2/21 | 3/20 | 1/14 | — | — | — | — | — | — |
| Blood creatine phosphokinase increasedInvestigations | 3/21 | 4/21 | 2/20 | 1/21 | 1/20 | 0/14 | — | — | — | — | — | — |
Full Analysis set (FAs): The Full Analysis Set (FAS) comprised all subjects to whom study treatment was assigned by randomization for arms 1 to 4. Full Analysis Set Asciminib single agent cohort (FAS-ASAC) includes all subjects assigned to the ASAC.
| Age, Customized(Participants) | Asciminib 40mg QD + Imatinib 400mg QD | Asciminib 60mg QD + Imatinib 400mg QD | Imatinib 400mg QD | Nilotinib 300mg BID | Asciminib 80mg QD | Total |
|---|---|---|---|---|---|---|
| 18 - <65 years | 18 | 19 | 16 | 19 | 14 | 86 |
| 65 - <85 years | 3 | 2 | 5 | 2 | 6 | 18 |
| Sex: Female, Male(Participants) | Asciminib 40mg QD + Imatinib 400mg QD | Asciminib 60mg QD + Imatinib 400mg QD | Imatinib 400mg QD | Nilotinib 300mg BID | Asciminib 80mg QD | Total |
|---|---|---|---|---|---|---|
| Female | 8 | 5 | 5 | 6 | 8 | 32 |
| Male | 13 | 16 | 16 | 15 | 12 | 72 |
| Race/Ethnicity, Customized(Participants) | Asciminib 40mg QD + Imatinib 400mg QD | Asciminib 60mg QD + Imatinib 400mg QD | Imatinib 400mg QD | Nilotinib 300mg BID | Asciminib 80mg QD | Total |
|---|---|---|---|---|---|---|
| White | 17 | 15 | 19 | 16 | 20 | 87 |
| Chinese | 0 | 0 | 0 | 1 | 0 | 1 |
| Indian | 0 | 1 | 0 | 0 | 0 | 1 |
| Korean | 1 | 2 | 1 | 1 | 0 | 5 |
| Missing - Asian | 3 | 1 | 0 | 2 | 0 | 6 |
| Missing - Overall | 0 | 2 | 1 | 1 | 0 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Nov 2018 to primary completion in Nov 2021, 35 months.
Results were first posted in Feb 2025, 3 years 3 months after primary completion. A results delay was requested in Oct 2022.
Of 25 industry-sponsored phase 2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 69. This study's 35 months is below that.
Counting every sponsor, half of 126 studies reached it within 73 months; a quarter within 43 and three quarters within 124.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Imatinib · Asciminib
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →